IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.

IF 2 4区 医学 Q3 ONCOLOGY Oncology Research Pub Date : 2024-08-23 eCollection Date: 2024-01-01 DOI:10.32604/or.2024.048315
Ziyong Liu, Tao Ma, Jinfang Li, Wei Ren, Zhixin Zhang
{"title":"IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.","authors":"Ziyong Liu, Tao Ma, Jinfang Li, Wei Ren, Zhixin Zhang","doi":"10.32604/or.2024.048315","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interleukin 13 receptor subunit alpha 2 (IL13RA2) plays an essential role in the progression of many cancers. However, the role of IL13RA2 in infantile haemangioma (IH) is still unknown.</p><p><strong>Materials and methods: </strong>IL13RA2 expression in IH tissues was analyzed using western blot, qRT-PCR, and immunofluorescence. The role of IL13RA2 in haemangioma-derived endothelial cells (HemECs) was determined following knockdown or overexpression of IL13RA2 using CCK-8, colony formation, apoptosis, wound healing, tubule formation, Transwell, and western blot.</p><p><strong>Results: </strong>IL13RA2 expression was upregulated in IH tissues. IL13RA2 overexpression promoted proliferation, migration, and invasion of HemECs and induced glycolysis, which was confirmed with a glycolysis inhibitor. Specifically, IL13RA2 interacted with β-catenin and activated the Wnt/β-catenin pathway in HemECs, which were involved in the above-mentioned effects of IL13RA2.</p><p><strong>Conclusions: </strong>These findings revealed that targeting IL13RA2 is a potential therapeutic approach for IH.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361910/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.048315","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Interleukin 13 receptor subunit alpha 2 (IL13RA2) plays an essential role in the progression of many cancers. However, the role of IL13RA2 in infantile haemangioma (IH) is still unknown.

Materials and methods: IL13RA2 expression in IH tissues was analyzed using western blot, qRT-PCR, and immunofluorescence. The role of IL13RA2 in haemangioma-derived endothelial cells (HemECs) was determined following knockdown or overexpression of IL13RA2 using CCK-8, colony formation, apoptosis, wound healing, tubule formation, Transwell, and western blot.

Results: IL13RA2 expression was upregulated in IH tissues. IL13RA2 overexpression promoted proliferation, migration, and invasion of HemECs and induced glycolysis, which was confirmed with a glycolysis inhibitor. Specifically, IL13RA2 interacted with β-catenin and activated the Wnt/β-catenin pathway in HemECs, which were involved in the above-mentioned effects of IL13RA2.

Conclusions: These findings revealed that targeting IL13RA2 is a potential therapeutic approach for IH.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IL13RA2通过激活糖酵解和Wnt/β-catenin信号通路促进婴儿血管瘤的进展。
背景:白细胞介素13受体亚基α2(IL13RA2)在许多癌症的发展过程中起着至关重要的作用。然而,IL13RA2在婴儿血管瘤(IH)中的作用尚不清楚:采用Western印迹、qRT-PCR和免疫荧光分析了IL13RA2在IH组织中的表达。通过CCK-8、菌落形成、细胞凋亡、伤口愈合、小管形成、Transwell和Western blot检测IL13RA2被敲除或过表达后在血管瘤衍生内皮细胞(HemECs)中的作用:结果:IL13RA2在IH组织中表达上调。结果:IL13RA2 在 IH 组织中表达上调,IL13RA2 的过表达促进了血液活细胞的增殖、迁移和侵袭,并诱导了糖酵解,糖酵解抑制剂证实了这一点。具体而言,IL13RA2与β-catenin相互作用,激活了血红素细胞中的Wnt/β-catenin通路,而Wnt/β-catenin通路参与了IL13RA2的上述作用:这些发现揭示了以IL13RA2为靶点是治疗IH的一种潜在方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
期刊最新文献
COL4A2 enhances thyroid cancer cell proliferation through the AKT pathway. Comparative analysis of breast and lung cancer survival rates and clinical trial enrollments among rural and urban patients in Georgia. Correction: Long non-coding RNA LINC02163 accelerates malignant tumor behaviors in breast cancer by regulating the microRNA-511-3p/HMGA2 axis as a competing endogenous RNA. Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2. IL13RA2 promotes progression of infantile haemangioma by activating glycolysis and the Wnt/β-catenin signaling pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1